We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biopharmaceutical companies Kamada and Kedrion Biopharma have partnered to develop, manufacture and distribute a human plasma-derived polyclonal immunoglobulin (IgG) product for potential Covid-19 treatment.